{
    "nctId": "NCT01016886",
    "briefTitle": "Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research",
    "officialTitle": "A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Heart Failure",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 99,
    "primaryOutcomeMeasure": "The primary objective is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular (LV) remodeling among women with HER2+ early breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic diagnosis of HER2 positive breast carcinoma\n* Eligible to receive trastuzumab\n* Age \\> 18 years\n* Able to give informed consent\n* No contraindications to MRI\n\nExclusion Criteria:\n\n* Known contraindication to beta-blocker therapy\n* Known contraindication to ACEI therapy\n* Current treatment with ACEI or beta blocker for other indication\n* History of heart failure, cardiomyopathy or baseline LVEF \\< 50%",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}